CTRI/2022/01/039257尚未招募未知
A randomized, double-blind placebo controlled study of clinical utility of multiple ketamine infusion in treatment resistant Obsessive Compulsive Disorder
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Participants must be willing to give a written informed consent document;
- •Participants must fulfill DSM-5 criteria for Obsessive Compulsive Disorder, and should have been resistant to at least 2 SSRI trails of adequate dose and duration and psychotherapy.
- •Participants must be medically and neurologically healthy.
排除标准
- •Those who have neurological disorders, severe medical illness, mental retardation and co-morbid psychiatric diagnoses such as psychosis, substance dependence
- •Women who are pregnancy or breastfeeding
- •Those who are allergic to ketamine
研究者
相似试验
进行中（未招募）
不适用
Evaluation of the effect of choline-stabilized orthosilicic acid (ch-OSA®) in patients with tennis elbowateral epicondylitisMusculoskeletal DiseasesLateral epicondylitisISRCTN12631735Bio Minerals NV148
进行中（未招募）
Unknown
Efficacy of herbal supplements (CL22209 and CL22205) on polycystic ovary syndrome (PCOS)CTRI/2023/11/059457CLS Pvt Ltd
进行中（未招募）
不适用
Safety, tolerability, pharmacokinetics and preliminary pharmacodynamics of QBW251 in healthy subjects and cystic fibrosis patients.MedDRA version: 16.1Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disorderscystic fibrosisEUCTR2011-005085-37-IEovartis Pharma Services AG156
进行中（未招募）
不适用
Safety, tolerability, pharmacokinetics and preliminary pharmacodynamics of QBW251 in healthy subjects and cystic fibrosis patients.cystic fibrosisEUCTR2011-005085-37-FRovartis Pharma Services AG140
进行中（未招募）
不适用
Safety, tolerability, pharmacokinetics and preliminary pharmacodynamics of QBW251 in healthy subjects and cystic fibrosis patients.MedDRA version: 17.1Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disorderscystic fibrosisEUCTR2011-005085-37-BEovartis Pharma Services AG156